Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Seedling fibroid characterization using optical coherence tomography.

Created on 16 Jul 2026

Authors

Arielle S Joasil, Daniella M Fodera, Zhuoya Shi, Sunny Hu, Aidan M Therien, Haiqiu Yang, Xiaowei Chen, Kristin M Myers, Christine P Hendon

Published in

Biomedical optics express. Volume 17. Issue 7. Pages 3386-3397. Jul 01, 2026. Epub Jun 02, 2026.

Abstract

Uterine leiomyomas, or fibroids, are the most common benign tumors in women. Despite this, the patient and healthcare burdens are immense. Symptoms include heavy and irregular bleeding, anemia, and impacts on fertility. Treatment options are limited, and fibroids are typically treated with hysterectomy. Current imaging modalities used for diagnosis and surgical planning cannot resolve smaller, or seedling, fibroids. If fibroids remain after surgery, they can continue to grow and require additional interventions. In this work, we characterize human seedling fibroids using optical coherence tomography (OCT). Statistical testing reveals significant differences between fibroid and normal specimens in OCT-based texture, statistical, and frequency-based features, as well as in collagen fiber architecture quantification. With its micron-resolution and near-real-time imaging speed, OCT has the potential to elucidate the microstructural characteristics of seedling fibroids, aiding in diagnosis and surgical planning.

PMID:
42460359
Bibliographic data and abstract were imported from PubMed on 16 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement